A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

The SMC has also has accepted Cladribine, also known as Mavenclad, for the treatment of relapsing-remitting multiple ...

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus FLOT yields better outcomes than FLOT alone.

Durvalumab is an IV drug that boosts the immune system’s ability to detect and kill cancer cells. It’s used to treat a range ...

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, ...

An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...

Data shows adding durvalumab (Imfinzi) to the standard chemotherapy combination known as FLOT before and after surgery kept ...

ASCO annual meeting featured a urothelial carcinoma oral abstract session and a discussant presentation by Dr. John Sfakianos ...

Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...